A Price Prediction Next Week
Based on the provided data and technical analysis, here is the prediction for Agilent Technologies (A) stock price for next trading week:
Technical Analysis
- RSI at 73.51 indicates overbought conditions, suggesting potential pullback
- MACD at 4.03 shows bullish momentum but may be losing steam
- 20-day SMA at $141.12 acts as near-term support
- 200-day SMA at $137.91 provides longer-term support
- Fibonacci levels show resistance at $152.31 and support at $137.75
News Analysis
- Healthcare sector expected to outperform in 2025 according to analysts
- Medical device makers like Agilent showing "hints of life" with 10%+ gains YTD
- Healthcare stocks historically gain 7.6% in first year of Republican presidential terms
Price Target Prediction for Next Week
- Base case: $145-148 range
- Bullish case: Test resistance at $152.31
- Bearish case: Pull back to support at $141.12
Trading Recommendation: SELL
- Stock appears overbought at current levels
- Technical indicators suggest potential short-term pullback
- Take profits and wait for better entry points around $141-142 support level
The stock is likely to consolidate or pull back next week given the overbought conditions, despite positive sector outlook. Traders should consider taking profits at current levels and look to re-enter on dips.
A Similar Chart Price Prediction
The price of A is predicted to go up -1.65%, based on the high correlation periods with LNW. The similarity of these two price pattern on the periods is 98.49%.
A
LNW
Down: -1.65%Similarity: 98.49%
A Revenue Forecast
A EPS Forecast
A FAQs
What is revenue forecast for next quarter？
What is eps forecast for next quarter？
A VS S&P500
Agilent's innovation engine and cost control efforts have been on display through strong growth and margin expansion since spinning out its electronic measurement business Keysight in November 2014.
As a well-established leader in many of its core markets, regulatory concerns and customer familiarity with Agilent's instrumentation and services can make market share gains for competitors difficult.
Agilent continues to increase its exposure to the sticky biopharmaceutical end market, including recent acquisitions in the emerging cell analysis field.
A Analyst's Forecast
Derik De Bruin
B of A Securities
Hold
Price Target
$153 → $150
Upside
+7.97%
BofA lowered the firm's price target on Agilent to $150 from $153 and keeps a Neutral rating on the shares. The Life Sciences Tools sector underperformed again in FY24 as Pharma and Biotech customers reined in spending after overspending during the pandemic and China remained "very subdued," the analyst tells investors. Entering 2025, "the setup is almost identical, so there is a healthy dose of skepticism among investors who have been burned over the past year," says the firm, which adds that thinks "there are finally some encouraging signs on the horizon." In conjunction with its year ahead preview for the group, the firm adjusted a number of price targets.
Luke Sergott
Barclays
Sell
Price Target
$145 → $135
Upside
-2.24%
Eve Burstein
Bernstein
Hold
Price Target
$140 → $135
Upside
+2.01%